Ryght AI Assembles Renowned Medical Leaders to Guide Next Phase of Clinical Trial AI Innovation

LAGUNA BEACH, Calif., Oct. 7, 2025 /PRNewswire/ -- Ryght AI, the clinical trials technology company behind breakthrough AI Site Twin technology, today announced the formation of its inaugural Scientific Advisory Board (SAB). This distinguished board will guide the company's research initiatives and strategic direction as it transforms clinical trial site selection, qualification, and activation through dynamic digital replicas of research facilities globally.

The SAB comprises globally recognized experts in oncology, hematology, dermatology, artificial intelligence, healthcare technology, and digital transformation. These leaders will provide Ryght AI with deep scientific and clinical insights, foster collaborative research with sponsors, and ensure the company's platform  roadmap aligns with real-world challenges in study feasibility, patient recruitment, and operational performance.

Driving Scientific Excellence with Global Impact

"Traditional approaches to clinical trial feasibility and operations have been hampered by static, outdated data," said Chadi Nabhan, MD, MBA, Chief Medical Officer and Head of Strategy at Ryght AI, who will chair the SAB. "Our Scientific Advisory Board brings together some of the brightest minds in medicine and research. Their expertise will help us accelerate innovation, scale our research operations, and make impactful strategic decisions as we expand the reach of our technology to help patients worldwide. We are thrilled to welcome these leaders who share our commitment to ethical AI and positive societal impact."

The SAB will collaborate closely with Ryght AI's leadership and R&D teams to:

• Guide the scaling of Ryght AI's research and development engines and global collaborations
• Support strategic decision-making and product direction
• Strengthen scientific rigor across all initiatives
• Facilitate partnerships with academic, clinical, and research institutions

Expert Voices on the Future of Clinical Trials

"Tackling the challenges of modern clinical trials demands technology that can automate complexity and generate meaningful insights at speed," said Manmeet Ahluwalia, MD, MBA, Chief of Medical Oncology, Chief Scientific Officer, and Deputy Director at Baptist Health Miami Cancer Institute. "Ryght's secure, generative AI platform and global research site network are well positioned to transform clinical research, helping bring therapies to patients faster and with greater efficiency."

"By leveraging Ryght's technology and network, trial sponsors can identify optimal  clinical trial sites, accelerate recruitment, and streamline complex workflows of the entire trial continuum to get therapies to market months or even years ahead of target and at lower cost," said Razelle Kurzrock, MD, Professor and Associate Director of the Cancer Center at the Medical College of Wisconsin.

Inaugural Members of the Scientific Advisory Board

• Manmeet Ahluwalia, MD, MBA, FASCO
  Chief of Medical Oncology, Chief Scientific Officer, and Deputy Director, Baptist Health Miami Cancer Institute 
• Neeraj Agarwal, MD, FASCO
  Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute 
• Tanios Bekaii-Saab, MD
  Chairman for the Division of Hematology/Medical Oncology, Mayo Clinic
• Rafael Fonseca, MD
  Chief Innovation Officer, Mayo Clinic in Arizona
• Siavash Jabbari, MD
  Medical Director of Radiation Oncology, Sharp Memorial Laurel Amtower Cancer Institute and Neuro-Oncology Center
• Elias Jabbour, MD
  Professor of Medicine in Department of Leukemia, MD Anderson Cancer Center
• Razelle Kurzrock, MD
  Founding Director, Michels Rare Cancers Research Laboratories, Medical College of Wisconsin
• Rana McKay, MD
  Associate Professor of Medicine, University of California in San Diego
• Dedee F. Murrell, MD, MA, BMBCh, FRCP
  Professor and Head, Department of Dermatology, St George Hospital
• Alan Skarbnik, MD
  Director, Lymphoma & CLL Program, Director Immune Effector Cell Therapeutics Program, Novant Health
• Vivek Subbiah, MD
  Chief, Early-Phase Drug Development, Sarah Cannon Research institute
• Greg Vidal, MD, PhD
  Director of Clinical Research and Lead of the Breast Cancer Program, West Cancer Center and Research Institute

About Ryght AI
Ryght AI is transforming clinical trial timelines with a cutting-edge intelligent platform powered by AI Site Twins, which are dynamic data models representing every clinical research site in the world. This innovative approach empowers sponsors and CROs to significantly accelerate clinical trial study startup through faster site selection and streamlined feasibility workflows, all powered by advanced generative and agentic AI. Furthermore, Ryght's SOC Type 2-compliant platform enhances efficiency by fostering seamless, real-time communication between sponsors, CROs, and research sites.

For more information, please visit www.ryght.ai. To discuss AI-powered clinical trial solutions or network membership for your site, CRO or sponsor company, please email [email protected].

Media Contact:
Ariel Paradis
[email protected]

SOURCE Ryght